These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 21740957

  • 1. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
    Matos CA, de Macedo-Ribeiro S, Carvalho AL.
    Prog Neurobiol; 2011 Sep 15; 95(1):26-48. PubMed ID: 21740957
    [Abstract] [Full Text] [Related]

  • 2. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM, Tran HD, Zalachoras I, Pepers BA, Meijer OC, den Dunnen JT, van Ommen GJ, Aartsma-Rus A, van Roon-Mom WM.
    Neurobiol Dis; 2013 Oct 15; 58():49-56. PubMed ID: 23659897
    [Abstract] [Full Text] [Related]

  • 3. Proteotoxic stress increases nuclear localization of ataxin-3.
    Reina CP, Zhong X, Pittman RN.
    Hum Mol Genet; 2010 Jan 15; 19(2):235-49. PubMed ID: 19843543
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.
    Williams AJ, Knutson TM, Colomer Gould VF, Paulson HL.
    Neurobiol Dis; 2009 Mar 15; 33(3):342-53. PubMed ID: 19084066
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
    Xiao H, Tang J, Hu Z, Tan J, Tang B, Jiang Z.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb 15; 27(1):23-8. PubMed ID: 20140862
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
    Switonski PM, Szlachcic WJ, Krzyzosiak WJ, Figiel M.
    Neurobiol Dis; 2015 Jan 15; 73():174-88. PubMed ID: 25301414
    [Abstract] [Full Text] [Related]

  • 10. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
    Saunders HM, Gilis D, Rooman M, Dehouck Y, Robertson AL, Bottomley SP.
    Protein Sci; 2011 Oct 15; 20(10):1675-81. PubMed ID: 21780213
    [Abstract] [Full Text] [Related]

  • 11. [Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease].
    Jia D, Jiang H, Tang B.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec 15; 25(6):660-2. PubMed ID: 19065526
    [Abstract] [Full Text] [Related]

  • 12. Nucleocytoplasmic shuttling activity of ataxin-3.
    Macedo-Ribeiro S, Cortes L, Maciel P, Carvalho AL.
    PLoS One; 2009 Jun 08; 4(6):e5834. PubMed ID: 19503814
    [Abstract] [Full Text] [Related]

  • 13. Polyglutamine expansion diseases: More than simple repeats.
    Silva A, de Almeida AV, Macedo-Ribeiro S.
    J Struct Biol; 2018 Feb 08; 201(2):139-154. PubMed ID: 28928079
    [Abstract] [Full Text] [Related]

  • 14. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
    Alves S, Régulier E, Nascimento-Ferreira I, Hassig R, Dufour N, Koeppen A, Carvalho AL, Simões S, de Lima MC, Brouillet E, Gould VC, Déglon N, de Almeida LP.
    Hum Mol Genet; 2008 Jul 15; 17(14):2071-83. PubMed ID: 18385100
    [Abstract] [Full Text] [Related]

  • 15. Compromised mitochondrial complex II in models of Machado-Joseph disease.
    Laço MN, Oliveira CR, Paulson HL, Rego AC.
    Biochim Biophys Acta; 2012 Feb 15; 1822(2):139-49. PubMed ID: 22037589
    [Abstract] [Full Text] [Related]

  • 16. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.
    Gonçalves N, Simões AT, Cunha RA, de Almeida LP.
    Ann Neurol; 2013 May 15; 73(5):655-66. PubMed ID: 23625556
    [Abstract] [Full Text] [Related]

  • 17. Toward understanding Machado-Joseph disease.
    Costa Mdo C, Paulson HL.
    Prog Neurobiol; 2012 May 15; 97(2):239-57. PubMed ID: 22133674
    [Abstract] [Full Text] [Related]

  • 18. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability.
    Durcan TM, Kontogiannea M, Thorarinsdottir T, Fallon L, Williams AJ, Djarmati A, Fantaneanu T, Paulson HL, Fon EA.
    Hum Mol Genet; 2011 Jan 01; 20(1):141-54. PubMed ID: 20940148
    [Abstract] [Full Text] [Related]

  • 19. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
    Colomer Gould VF, Goti D, Pearce D, Gonzalez GA, Gao H, Bermudez de Leon M, Jenkins NA, Copeland NG, Ross CA, Brown DR.
    Neurobiol Dis; 2007 Sep 01; 27(3):362-9. PubMed ID: 17632007
    [Abstract] [Full Text] [Related]

  • 20. Machado-Joseph disease/spinocerebellar ataxia type 3.
    Paulson H.
    Handb Clin Neurol; 2012 Sep 01; 103():437-49. PubMed ID: 21827905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.